Financial health
as filed2.3/10
Is it financially healthy right now?
ROE -103%: lost 103¢ per shareholder dollar. Leverage 30%: owes 30¢ per asset dollar.
weight 45% of this tense · 23rd percentile among 147 sector filers · read for itself
From the record
Return on equity: in the fiscal year ended 2025-12-31, Scinai Immunotherapeutics Ltd. lost about 103 cents for every dollar of shareholders' money, and gross profitability: its products earned less than nothing, about minus 23 cents per dollar of everything the company owns. Leverage: it owed about 30 cents per dollar of assets, and net share issuance: its share count grew 189.6% over the year (the filed statements).
What it rests on
- what it owes per dollar of assetstop 44% of its family
- return on equitybottom 28% of its family
- gross profit against assetsbottom 1% of its family
- the share count against the year beforebottom 8% of its family
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Industry position
as filed4.9/10
How strong is its position in its industry?
bottom 49% of 102 in its family; net margin -633.6%.
weight 22% of this tense · 49th percentile among 102 sector filers · read for its customers
From the record
Scinai Immunotherapeutics Ltd.'s standing among 102 graded names in its industry family: revenue of $1 million in fiscal 2025 ranks in the bottom 21% by size; a net margin of -633.6% ranks in the bottom 40%; revenue growth of 99.3% a year over the last 1 filed years ranks in the top 14% (its annual reports).
What it rests on
- revenue against the family$1.3Mbottom 21% of its family
- net margin-633.6%bottom 40% of its family
- three-year revenue growth99.3%top 14% of its family
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Leadership
SI estimate5.0/10
What are the people in charge doing?
SI estimate 5.0/10, confidence 20 of 100 (family median).
weight 33% of this tense · 50th percentile among 130 sector filers · read for its shareholders
SI estimate Inferred, not read as filed
- Why it is an estimate
- It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2023-01-03 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.9 years and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 130 members with one.
- What the record cannot read
- It files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2023-01-03 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.9 years and cannot see past it; a floor under five years is not read as years in charge.
- How it was reasoned
- family median, 130 readings behind it.
- Confidence
- 20 of 100
- What would change it
- Its next annual report on file with the inputs replaces this estimate with the filed reading.
From the record
SI estimate, not a filed reading: Scinai Immunotherapeutics Ltd.'s leadership is put at 5.0 of 10 with a confidence of 20 of 100, because it files no Form 8-K (a foreign issuer reports on Form 6-K), so officer and director changes cannot be read there; the record of its people begins on 2023-01-03 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 3.9 years and cannot see past it; a floor under five years is not read as years in charge, so the desk assumes the typical reading of its industry family, the median of 130 members with one. Its next annual report on file with the inputs replaces this estimate with the filed reading.